CTOs on the Move

Seniorlink

www.seniorlink.com

 
Seniorlink is a tech-enabled health services company transforming care management in the home. For over 15 years, we`ve pioneered solutions for caregivers, including our compassionate technology of Vela, and our unique in-home model of Caregiver Homes. These innovative approaches have earned Caregiver Homes recognition as the first community-based organization to receive the National Committee for Quality Assurance`s (NCQA) highest level of accreditation for Case Management. Today, we remain fully committed to caregivers, supporting them at every step with resources, advocacy and insights as they fulfill their promise to a loved one. We value your contribution to this important mission, and ...
  • Number of Employees: 250-1000
  • Annual Revenue: $10-50 Million

Executives

Name Title Contact Details

Similar Companies

Trenton Orthopaedic Group, PA

Trenton Orthopaedic Group, PA is a Trenton, NJ-based company in the Healthcare, Pharmaceuticals, and Biotech sector.

The American Board of Physical Medicine and Rehabilitation

The American Board of Physical Medicine and Rehabilitation is a Rochester, MN-based company in the Healthcare, Pharmaceuticals, and Biotech sector.

St. John`s Episcopal Hospital

Episcopal Health Services (EHS) traces its roots almost 150 years back to the Church Charity Foundation which was founded on February 6, 1851 for aged indigent persons and for the welfare of orphans, half orphans, and other destitute children.

APC, Inc.

APC, Inc. is one of the leading providers in Healthcare, Pharmaceuticals, and Biotech. It is based in Ankeny, IA. To find more information about APC, Inc., please visit www.amerprotcorp.com

MolecularMD

MolecularMD founders Brian Druker (lead clinical investigator for Gleevec, the first molecularly-targeted anticancer agent) and Sheridan G. Snyder (entrepreneur, founder of Genzyme and Upstate Biotechnology) came together with the mission of providing precise, standardized molecular testing for new oncology drugs. The company’s initial accomplishment was in developing and implementing the only standardized assay for quantification of BCR-ABL expression levels, which proved critical to pharmaceutical sponsors in satisfying regulators for approval of the second-generation ABL kinase inhibitors nilotinib (Tasigna, Novartis) and dasatinib (Sprycel, BMS). With that foundational success in supporting pivotal international studies with centralized, high-quality diagnostic services, MolecularMD has become a preferred provider of molecular diagnostics products and services to pharmaceutical and biotech drug developers. Capabilities range from specialty molecular testing services performed in MolecularMD’s centralized CLIA-certified and CAP-accredited laboratory, to development of FDA approved companion diagnostics to support new drug registrations.